Lu Bin, Luo Jiahui, Yan Yike, Zhang Yuhan, Luo Chenyu, Li Na, Zhou Yueyang, Wu Dong, Dai Min, Chen Hongda
Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Center for Prevention and Early Intervention, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Lancet Reg Health West Pac. 2024 Aug 19;51:101172. doi: 10.1016/j.lanwpc.2024.101172. eCollection 2024 Oct.
Evidence on the long-term benefits and cost-effectiveness of colorectal cancer (CRC) screening strategies in China remains limited. This modelling study aims to address this issue for various CRC screening strategies in China between 2020 and 2060.
Using a previously developed microsimulation model (MIMIC-CRC) with Chinese epidemiological data, we evaluated four CRC screening strategies targeting population aged 45-74 years: no screening, colonoscopy every 10 years, biennial faecal immunochemical testing (FIT), and a roll-out FIT screening strategy. Screening coverage (invitation) rates from 5% to 100% were analysed. Single-cohort analysis of 100,000 individuals was conducted to estimate the relative cost-effectiveness of each strategy. A multiple-cohort analysis of 100,000 people aged 40+ over 2020-2060 was conducted to project nation-wide long-term benefits and cost-effectiveness.
In single-cohort analysis, all strategies yielded reductions in CRC incidence and mortality compared to no screening, with colonoscopy outperforming FIT-based strategies at the same invitation rates. In multiple-cohort analysis, among people over 40 years of age in China over 2020-2060, compared to no screening, at invitation rate of 5%, screening by colonoscopy, biennial FIT and roll-out FIT-based approach were estimated to avert 1.2, 0.4, and 0.3 million incident CRCs and 0.2, 0.1, and 0.1 million CRC-related deaths, respectively, compared to no screening (25.4 million incident CRCs and 4.4 million CRC-related deaths), and this preventive effect enlarged as the screening coverage rate increased. At full coverage, colonoscopy achieved the largest reductions (38.2% lower incidence and 43.2% lower mortality) but required the most resources. Biennial FIT and roll-out FIT-based approach screening was slightly less effective but had significant reduced colonoscopy needs (reduction of 83.8% and 85.2%, respectively) and overall cost (reduction of 23.4% and 37.8%, respectively) compared to colonoscopy screening.
Nation-wide implementation of screening would be effective in reducing the burden of CRC in China. Biennial FIT and roll-out FIT-based screening strategies could prevent incident CRC cases and CRC-related deaths with considerably fewer resources than colonoscopy screening. Efforts should be made to increase the screening coverage in China.
Chinese Academy of Medical Science Innovation Fund for Medical Science (2022-I2M-1-0031); National Natural Science Foundation of China (82173606; 82273726); Beijing Nova Program of Science and Technology (20230484397).
中国结直肠癌(CRC)筛查策略的长期益处和成本效益方面的证据仍然有限。本建模研究旨在解决2020年至2060年间中国各种CRC筛查策略的这一问题。
使用先前开发的带有中国流行病学数据的微观模拟模型(MIMIC-CRC),我们评估了针对45至74岁人群的四种CRC筛查策略:不筛查、每10年进行一次结肠镜检查、每两年进行一次粪便免疫化学检测(FIT)以及逐步推行FIT筛查策略。分析了5%至100%的筛查覆盖率(邀请率)。对100,000名个体进行单队列分析,以估计每种策略的相对成本效益。对2020年至2060年间100,000名40岁以上人群进行多队列分析,以预测全国范围内的长期益处和成本效益。
在单队列分析中,与不筛查相比,所有策略均使CRC发病率和死亡率降低,在相同邀请率下,结肠镜检查优于基于FIT的策略。在多队列分析中,2020年至2060年间中国40岁以上人群中,与不筛查相比,在邀请率为5%时,结肠镜检查、每两年一次FIT和逐步推行基于FIT的方法筛查估计分别可避免120万、40万和30万例新发CRC以及20万、10万和10万例CRC相关死亡,而不筛查的情况下预计有2540万例新发CRC和440万例CRC相关死亡,并且随着筛查覆盖率的提高,这种预防效果会扩大。在全覆盖时,结肠镜检查实现的降低幅度最大(发病率降低38.2%,死亡率降低43.2%),但需要的资源最多。与结肠镜检查相比,每两年一次FIT和逐步推行基于FIT的方法筛查效果略差,但结肠镜检查需求显著减少(分别减少83.8%和85.2%),总体成本也显著降低(分别降低23.4%和37.8%)。
在全国范围内实施筛查将有效减轻中国CRC的负担。每两年一次FIT和逐步推行基于FIT的筛查策略相比结肠镜检查筛查,可用更少的资源预防新发CRC病例和CRC相关死亡。应努力提高中国的筛查覆盖率。
中国医学科学院医学科技创新基金(2022-I2M-1-0031);国家自然科学基金(82173606;82273726);北京市科技新星计划(20230484397)。